Begin typing your search above and press return to search.
SII says vaccine dose will be sold at Rs 1,000 per dose in private markets
By: Tupaki Desk | 12 Jan 2021 1:10 PM GMT
It is already known that the DCGI approved two vaccines, Oxford vaccine Covishield, developed by Serum Institute, and indigenously developed Covaxin of Bharat Biotech for emergency use in India.
The vaccine doses from both the pharma companies have left from the plants to the government for the massive vaccination program which will be started on the 16th of January across the nation.
The Pune-based Serum Institute of India (SII) has fixed a price of Oxford-AstraZeneca's COVID-19 vaccine - Covishield for the private markets.
The News Agency ANI quoted Serum Institute of India (SII) CEO Adar Poonawalla as saying, 100 million doses of vaccine doses were sold to the Indian government for Rs 200 per dose
He added that they have decided to not look for profits from the first 100 million doses as they want to support the nation and the Indian government.
"We have fixed the vaccine price at Rs 1,000 per dose in private markets. The plans are underway to bring the vaccine to everyone in the nation by manufacturing 70-80 million doses per month.," the CEO was quoted by the media reports.
The vaccine doses from both the pharma companies have left from the plants to the government for the massive vaccination program which will be started on the 16th of January across the nation.
The Pune-based Serum Institute of India (SII) has fixed a price of Oxford-AstraZeneca's COVID-19 vaccine - Covishield for the private markets.
The News Agency ANI quoted Serum Institute of India (SII) CEO Adar Poonawalla as saying, 100 million doses of vaccine doses were sold to the Indian government for Rs 200 per dose
He added that they have decided to not look for profits from the first 100 million doses as they want to support the nation and the Indian government.
"We have fixed the vaccine price at Rs 1,000 per dose in private markets. The plans are underway to bring the vaccine to everyone in the nation by manufacturing 70-80 million doses per month.," the CEO was quoted by the media reports.
